A groundbreaking research initiative aimed at developing new treatments for preeclampsia, a serious pregnancy complication, has received significant funding. Dr. Wendy Kuohung, an associate professor of obstetrics and gynecology at Boston University Chobanian & Avedisian School of Medicine, has been awarded a two-year Discovery Research Grant by March of Dimes. The grant, totaling $200,000, will support her investigation into the effects of APOL1 gene variants on preeclampsia. This research seeks to identify potential drug compounds that could mitigate the condition, particularly in Black women who are disproportionately affected. By focusing on genetic factors and conducting extensive screening of existing and novel drugs, this study aims to shed light on the underlying mechanisms of preeclampsia and pave the way for more effective therapies.

Preeclampsia is a complex disorder that poses significant risks to both mother and baby. Typically manifesting after 20 weeks of pregnancy, it is characterized by high blood pressure, swelling, and protein in the urine. Despite its prevalence and severity, therapeutic advancements have lagged for over a century. Dr. Kuohung's innovative approach involves creating cell lines that express APOL1 gene variants, which are linked to increased susceptibility to preeclampsia, especially among Black women. Through this method, she plans to screen hundreds of drug compounds to find those that can reduce cellular stress markers associated with the condition. This process may uncover promising candidates for new drug therapies.

The importance of this research extends beyond identifying potential treatments. It also delves into understanding how preeclampsia develops, particularly in relation to genetic mutations. Dr. Kuohung’s work will involve pioneering studies using placental cells carrying APOL1 variants. These experiments aim to unravel the pathophysiological mechanisms behind preeclampsia, providing valuable insights into why certain populations are more vulnerable. Her findings could lead to targeted interventions that address the disparities in maternal health outcomes.

In addition to her clinical expertise in reproductive health, Dr. Kuohung brings a wealth of experience in addressing health inequities. As director of the Division of Reproductive Endocrinology at Boston Medical Center, she has dedicated her career to improving reproductive care and exploring the microbiome of the reproductive tract. Her background in infertility treatment, in vitro fertilization, and minimally invasive surgery adds depth to her research endeavors. The March of Dimes, a nonprofit organization committed to improving maternal and infant health, recognizes the potential impact of her work in advancing women’s health and reducing health disparities.

This research holds the promise of transforming the landscape of preeclampsia treatment. By identifying lead compounds that effectively target the condition, Dr. Kuohung’s study could provide critical tools for healthcare providers. Moreover, her work may offer new perspectives on the biological processes involved in preeclampsia, ultimately contributing to better health outcomes for mothers and infants. The success of this project could mark a significant step forward in addressing the maternal health crisis, particularly among marginalized communities.